These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 32091254)

  • 1. The Promise of CRISPR for Human Germline Editing and the Perils of "Playing God".
    Locke LG
    CRISPR J; 2020 Feb; 3(1):27-31. PubMed ID: 32091254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ethical Considerations in Therapeutic Clinical Trials Involving Novel Human Germline-Editing Technology.
    Brokowski C; Adli M
    CRISPR J; 2020 Feb; 3(1):18-26. PubMed ID: 32091258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ordo-Responsibility for Germline Gene Editing.
    Ranisch R; Rudolph T; Cremer HJ; Knoepffler N
    CRISPR J; 2020 Feb; 3(1):37-43. PubMed ID: 32091257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ethics and Global Governance of Human Germline Genome Editing: The Problem of Techno-Scientific Colonialist Paternalism.
    Arguedas-Ramírez G
    CRISPR J; 2020 Apr; 3(2):83-88. PubMed ID: 32315224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Procreative Non-Maleficence: A South African Human Rights Perspective on Heritable Human Genome Editing.
    Thaldar D; Shozi B
    CRISPR J; 2020 Feb; 3(1):32-36. PubMed ID: 32091250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Foresight is 2020: Ten Bold Predictions for the New CRISPR Year.
    Barrangou R
    CRISPR J; 2019 Dec; 2(6):341-342. PubMed ID: 31860348
    [No Abstract]   [Full Text] [Related]  

  • 7. Refining CRISPR-based genome and epigenome editing off-targets.
    Luo Y
    Cell Biol Toxicol; 2019 Aug; 35(4):281-283. PubMed ID: 31227932
    [No Abstract]   [Full Text] [Related]  

  • 8. CRISPR off-targets: a question of context.
    Haeussler M
    Cell Biol Toxicol; 2020 Feb; 36(1):5-9. PubMed ID: 31734746
    [No Abstract]   [Full Text] [Related]  

  • 9. Human germline editing in the era of CRISPR-Cas: risk and uncertainty, inter-generational responsibility, therapeutic legitimacy.
    Schleidgen S; Dederer HG; Sgodda S; Cravcisin S; Lüneburg L; Cantz T; Heinemann T
    BMC Med Ethics; 2020 Sep; 21(1):87. PubMed ID: 32912206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRISPR-Cas9 for cancer therapy: Opportunities and challenges.
    Chen M; Mao A; Xu M; Weng Q; Mao J; Ji J
    Cancer Lett; 2019 Apr; 447():48-55. PubMed ID: 30684591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The trust game: CRISPR for human germline editing unsettles scientists and society.
    Braun M; Meacham D
    EMBO Rep; 2019 Feb; 20(2):. PubMed ID: 30602586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The promise and challenge of therapeutic genome editing.
    Doudna JA
    Nature; 2020 Feb; 578(7794):229-236. PubMed ID: 32051598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thinking About CRISPR: The Ethics of Human Genome Editing.
    Barrangou R
    CRISPR J; 2019 Oct; 2(5):247-248. PubMed ID: 31599676
    [No Abstract]   [Full Text] [Related]  

  • 14. CRISPR-Cas9-Based Genome Editing in the Silverleaf Whitefly (
    Heu CC; McCullough FM; Luan J; Rasgon JL
    CRISPR J; 2020 Apr; 3(2):89-96. PubMed ID: 32315225
    [No Abstract]   [Full Text] [Related]  

  • 15. Why CRISPR babies are still too risky - embryo studies highlight challenges.
    Ledford H
    Nature; 2023 Mar; 615(7953):568-569. PubMed ID: 36914863
    [No Abstract]   [Full Text] [Related]  

  • 16. Germline Genome Editing Research: What Are Gamete Donors (Not) Informed About in Consent Forms?
    Niemiec E; Howard HC
    CRISPR J; 2020 Feb; 3(1):52-63. PubMed ID: 32091253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of CRISPR/Cas Genome Editing Technology for Targeted Mutagenesis in Rice.
    Xu R; Wei P; Yang J
    Methods Mol Biol; 2017; 1498():33-40. PubMed ID: 27709567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Crispr Future for Gene-Editing Regulation: a Proposal for an Updated Biotechnology Regulatory System in an Era of Human Genomic Editing.
    Tomlinson T
    Fordham Law Rev; 2018 Oct; 87(1):437-83. PubMed ID: 30296034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A society-wide conversation is needed about germline genome editing using CRISPR.
    Birney E
    Nat Med; 2024 Jan; 30(1):30-32. PubMed ID: 38177854
    [No Abstract]   [Full Text] [Related]  

  • 20. CRISPR-Cas tools to study gene function in cytokinesis.
    Husser MC; Skaik N; Martin VJJ; Piekny A
    J Cell Sci; 2021 Apr; 134(8):. PubMed ID: 33912919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.